Alginate products with high G-content derived from seaweed harvesting are unable to meet current market demands. Global demand is already outstripping supply of food grade alginates, and there is increasing demand resulting from new applications within the food, pharmaceuticals, biotechnology and cosmetics industries. Existing harvesting methods have high production costs, are labour-intensive, and have low extraction yields (especially for low molecular weight G-rich alginates, where 75% of product is wasted). The global alginate market is projected to grow significantly and reach approximately €1 billion by 2028. AlgiPharma has been approached by several major pharmaceutical, biomedical, cosmetic and food clients who are eager for more sustainable and precisely defined alginate products, for their functionality, and in one case to replace components derived from petrochemicals. AlgiPharma has developed a land-based fermentation process but need to scale up this process to serve the global market. This is expected to create significant European competitive advantage in the global production of alginates. AlgiPharma has partnered with a consortium of industrial European partners to establish a unique European manufacturing base to supply these well-defined alginates. AlgiPharma's innovative approach is a sustainable land-based production method, providing a sustainable, scalable and cost-efficient production of highly sought after products. This new method also offers significant environmental and social benefits, providing an environmentally friendly and cost-effective alternative to traditional seaweed harvesting. EIC funding is essential to meet the high initial costs, de-risking the project for future investment, and will enable AlgiPharma to accelerate the scale-up process to promptly meet market demand for large scale production.